Gastric cancer treatment: recent progress and future perspectives.
Guan WL, He Y, Xu RH. · 2023
Read Gastric cancer treatment: recent progress and future perspectives. by Guan WL, He Y, Xu RH. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc10225110.txt.
Introduction
Guan, He, and Xu review recent progress and future prospects in gastric cancer treatment in a 2023 paper. Gastric, or stomach, cancer is among the most common cancers worldwide. Most patients are found at a late stage, because early symptoms are vague and screening is rare in many countries.
The review covers the main systemic treatments: chemotherapy, targeted drugs, and immune therapy. It explains which patients gain from each approach and how biomarkers guide the choice. It closes with trials and ideas that may improve the still poor outlook for advanced disease.
Catalog record
| CREATOR | Guan WL, He Y, Xu RH. |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 128 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Gastric cancer treatment: recent progress and future perspectives By Wen-Long Guan, Ye He, Rui-Hua Xu Published in: Journal of Hematology & Oncology DOI: 10.1186/s13045-023-01451-3 ABSTRACT Gastric cancer (GC) is one of the most common malignancies worldwide. Most patients are diagnosed at advanced stages due to the subtle symptoms of earlier disease and the low rate of regular screening. Systemic therapies for GC, including chemotherapy, targeted therapy and immunotherapy, have evolved significantly in the past few years. For resectable GC, perioperative chemotherapy has become the standard treatment. Ongoing investigations are exploring the potential benefits of targeted therapy or immunotherapy in the perioperative or adjuvant setting. For metastatic disease, there have been notable advancements in immunotherapy and biomarker-directed therapies recently. Classification based on molecular biomarkers, such as programmed cell death ligand 1 (PD-L1), microsatellite instability (MSI), and human epidermal growth factor receptor 2 (HER2), provides an opportunity to differentiate patients who may benefit from immunotherapy or targeted therapy. Molecular diagnostic techniques have facilitated the characterization of GC genetic profiles and the identification of new potential molecular targets. This review systematically summarizes the main research progress in systemic treatment for GC, discusses current individualized strategies and presents future perspectives. BACKGROUND Gastric cancer (GC) is the fifth most common malignant tumor and the fourth leading cause of cancer-associated death worldwide [1, 2]. The incidence varies geographically across the globe, with the highest incidence in Eastern Asia (Japan and Mongolia) and Eastern Europe, whereas incidence rates in Northern Europe and Northern America are generally low, comparable to African regions [2]. Notably, the incidence of gastric cancer among young adults (aged < 50 years) in recent years has been progressively rising in both low-risk and high-risk countries. Aside from Helicobacter Pylori infection, the occurrence of GC has been linked to genetic risk factors as well as lifestyle factors, such as alcohol consumption and smoking [3–6]. Despite the high incidence of GC, most patients are unfortunately diagnosed at advanced stages with dismal prognoses due to the lack of distinguishing clinical indications [7, 8]. Systemic chemotherapy is the mainstay treatment for metastatic GC (mGC), with a median overall survival (OS) of ~ 12 months for patients treated with conventional chemotherapy [9]. Intratumoral and intertumoral heterogeneity are the prominent features of GC that partly contribute to its poor prognosis. However, histological classifications alone are insufficient to effectively stratify patients for individualized treatment and improve patients’ clinical outcomes [10]. Therefore, cutting-edge diagnostic techniques and drugs are of fundamental importance for better characterizing molecular profiles and identifying potential novel therapeutic targets for GC patients [11–13]. Trastuzumab, a monoclonal antibody targeting Human Epidermal Receptor 2 (HER2), was the first approved targeted therapy for GC. However, after the ToGA study, progress in the development of treatments for gastric cancer stalled for nearly a decade [14]. Emerging advances in immunotherapy, particularly in anti-HER2 therapy, and various biomarker-directed therapies in GC have recently broken this trend. For example, anti-programmed cell death 1 (PD-1) antibodies have demonstrated impressive efficacy and prolonged survival in untreated MSI-H/dMMR mGC patients [15]. Substantial breakthroughs in the treatment of gastric cancer have been achieved with novel anti-HER2 therapeutic agents, such as T-DXd and disitamab vedotin (RC48) [16]. In addition, in light of the success of immunotherapy and targeted therapy as first-line treatments for advanced gastric cancer, ongoing research is investigating their potential to advance the treatment of patients with locally advanced stage GC. The treatment landscape of gastric cancer has evolved significantly in the past few years, with the emergence of new immunotherapy and targeted therapies for patients at various stages of the disease (Fig. 1). In this review, we systematically summarize the pivotal clinical trials in GC treatment and provide an update on the management of localized and metastatic gastric cancer. We also discuss the developments in immunotherapy and targeted therapy and highlight current individualized treatments and future perspectives.Fig. 1Updated immunotherapy and targeted therapy for gastric cancer. This algorithm provides guidance for selecting currently available immunotherapy and targeted therapy based on different biomarkers MANAGEMENT FOR LOCALIZED GC Radical surgery is the primary treatment for resectable gastric cancer. Several therapeutic approaches have been established to lower the risk of recurrence and improve long-term survival, including perioperative chemotherapy, adjuvant chemotherapy, and adjuvant chemoradiotherapy (Table 1). They are listed as the recommended treatments for resectable localized GC in current guidelines[5, 17, 18]. Further, the addition of targeted therapy and/or immune checkpoint inhibitors (ICIs) is currently being studied in the neoadjuvant/adjuvant setting.Table 1Summary of the key phase III clinical trials of perioperative and adjuvant chemotherapy in resectable GCTherapy lineTrialStageExperimental armControl armPrimary endpointsResult (Experimental vs. Control)ReferencesPerioperative chemotherapyMAGICStage II or higher3 × ECF → Surgery → 3 × ECFSurgeryOSPFS: HR 0.66; 95% CI 0.53–0.81; P < 0.001; 5-year OS: 36% vs. 23% (HR 0.75; 95% CI 0.60–0.93; P = 0.009)[19]FNCLCC & FFCDResectable2–3 × CF → Surgery → 3–4 × CFSurgeryOS5-year DFS: 34% v 19% (HR, 0.65; 95% CI 0.48 -0.89; P = 0.003) 5-year OS: 38% v 24% (HR, 0.69; 95% CI 0.50 -0.95; P = 0.02)[20]FLOT4-AIOcT2 or higher or N + 4 × FLOT → Surgery → 4 × FLOT3 × ECF/ECX → Surgery → 3 × ECF/ECXOSPFS: 30 vs. 18 months (HR 0.75; 95% CI 0.62–0.91; P = 0.0036); OS: 50 vs. 35 months (HR 0.77; 95% CI 0.63–0.94; P = 0.012)[21]PRODIGYcT2-3N + , or cT4Nany3 × DOS → Surgery → 8 × S-1Surgery → S-1PFS3-year PFS: 66.3% vs. 60.2% (HR 0.70; 95% CI, 0.52–0.95; P = 0.023); 3-year OS: 74.2% vs. 73.4% (HR 0.84; 95% CI, 0.60–1.19; P = 0.338)[22]RESOLVEcT4aN + or cT4bNanyArm C: 3 × SOX → Surgery → 5 × SOX → 3 × S-1Arm A: Surgery → 8 × CAPOXDFS3-year DFS: 59.4% vs. 51.1% (HR 0.77; 95% CI, 0.61–0.97; P = 0.028)[24]Adjuvant chemotherapyACTS-GCStage II or IIISurgery → S-1 for 1 yearSurgeryOS5-year OS: 71.7% vs. 61.1% (HR 0.669; 95% CI, 0.540 to 0.828)[27]CLASSICStage II-IIIBSurgery → 8 × CAPOXSurgeryDFS5-year DFS: 68% vs. 53% (HR 0.58; 95% CI, 0.47 to 0.72; P < 0.0001) 5-year OS: 78% vs. 69% (HR 0.66; 95% CI, 0.51 to 0.85; P = 0.0015)[25] [26]JACCRO GC-07Stage IIISurgery → 1 × S-1 → 7 × Docetaxel plus S-1 → S-1 for 1 yearSurgery → S-1 for 1 yearRFS3-year RFS: 66% vs. 50% (HR 0.632; 99.99% CI, 0.400 to 0.998; P < 0.001)[23]RESOLVEcT4aN + or cT4bNanyArm B: Surgery → 8 × SOXArm A: Surgery → 8 × CAPOXDFS3-year DFS: 56.5% vs. 51.1% (HR 0.86; 95% CI, 0.68 to 1.07; P = 0.17)[24] Perioperative chemotherapy Perioperative chemotherapy has become the standard treatment for resectable localized GC. Several clinical trials have demonstrated that perioperative chemotherapy could improve the prognosis of patients with resectable GC compared to surgery alone. The MAGIC trial marked a significant advancement in the field of perioperative chemotherapy for resectable GC. In this phase 3 study, 503 patients were enrolled with resectable gastric, gastroesophageal junction (GEJ), or lower esophageal adenocarcinoma. Patients in the experimental group received three preoperative and three postoperative cycles of epirubicin, cisplatin, and fluorouracil (ECF) [19]. The results showed that the perioperative ECF regimen could decrease tumor stage and significantly improve progression-free survival (PFS, HR 0.66; 95% CI 0.53–0.81, P < 0.001) and overall survival (OS, HR 0.75; 95% CI 0.60–0.93, P = 0.009). Another phase